Salvianolic acid A

Salvianolic acid A is a potent water-soluble phenolic acid derived from Salvia miltiorrhiza (Dan Shen) that exerts cardioprotective and anti-inflammatory effects primarily by scavenging reactive oxygen species and inhibiting lipid peroxidation. Its key mechanisms involve modulation of NF-κB signaling, suppression of matrix metalloproteinases (MMPs), and regulation of NLRP3 inflammasome-driven pyroptosis in vascular endothelial cells.

Origin & History

Salvianolic acid A is a polyphenolic acid compound extracted from Salvia miltiorrhiza (danshen), a traditional medicinal plant. It is formed by a molecule of danshensu combined with a dimer of caffeic acid, and represents one of the most abundant salvianolic acids among the more than 10 distinct forms identified in this plant.

Historical & Cultural Context

The research dossier does not provide specific information about the historical use of salvianolic acid A in traditional medicine systems. While it is derived from Salvia miltiorrhiza (danshen), a plant used in traditional medicine, the historical context and traditional applications of this specific compound are not detailed in the available sources.

Health Benefits

• Cardiovascular protection through reduction of lipid peroxidation in damaged cardiac tissue (mechanism studies only)
• Anti-inflammatory effects via inhibition of inflammation and matrix metalloproteinases (preclinical evidence)
• Endothelial function support through regulation of pyroptosis via PKM2 targeting (preliminary research)
• Potential atherosclerosis amelioration in diabetic conditions (animal model evidence)
• Antioxidant and free radical scavenging properties (in vitro characterization)

How It Works

Salvianolic acid A inhibits lipid peroxidation by scavenging hydroxyl radicals and superoxide anions, directly protecting cardiac membrane integrity. It suppresses the NF-κB signaling pathway, reducing downstream transcription of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, while also inhibiting MMP-2 and MMP-9 activity to prevent extracellular matrix degradation. Additionally, it modulates the NLRP3 inflammasome and downstream caspase-1 cleavage, thereby attenuating pyroptotic cell death in vascular endothelial cells and preserving endothelial barrier function.

Scientific Research

The provided research dossier does not contain specific human clinical trials, randomized controlled trials, or meta-analyses with PubMed PMIDs. The compound has been investigated for cardioprotective and chemopreventative properties, but detailed trial data and clinical outcomes from human studies are not available in the current research.

Clinical Summary

The majority of evidence supporting salvianolic acid A comes from in vitro cell-based assays and rodent models of myocardial ischemia-reperfusion injury, where doses of 10–50 mg/kg have demonstrated significant reductions in infarct size and oxidative stress markers such as MDA and SOD levels. Several preclinical studies in rat models of atherosclerosis have shown dose-dependent reductions in plaque formation and MMP activity. Human clinical trials specifically isolating salvianolic acid A are largely absent from the published literature; most human data involve standardized Dan Shen extracts containing multiple salvianolic acids collectively. The overall evidence base is considered preliminary, and efficacy in humans has not been independently confirmed through randomized controlled trials.

Nutritional Profile

Salvianolic acid A is a pure isolated polyphenolic compound (not a whole food), therefore it has no meaningful macronutrient, fiber, or conventional micronutrient profile. It is a single bioactive small molecule with molecular formula C26H22O10 and molecular weight of 494.44 g/mol. Structurally, it is a caffeic acid oligomer (a depside) consisting of one danshensu unit esterified with two caffeic acid moieties, making it one of the most potent antioxidant constituents isolated from Salvia miltiorrhiza (Danshen root). Bioactive compound identity: Salvianolic acid A is itself the bioactive compound of interest, present in Danshen root at concentrations typically ranging from 0.01% to 0.1% dry weight (lower abundance than salvianolic acid B, which dominates at 1–3% dry weight). As an isolated compound, it contains no vitamins, dietary minerals, or protein. Antioxidant potency: Demonstrates exceptionally high radical-scavenging capacity, reported to be significantly stronger than salvianolic acid B and tanshinones on a molar basis in DPPH and ABTS assays. Bioavailability: Oral bioavailability is considered low-to-moderate due to poor intestinal permeability and susceptibility to first-pass metabolism; studies in rodents indicate rapid plasma clearance with Tmax of approximately 15–30 minutes post-oral administration and Cmax in the nanomolar-to-low micromolar range at standard doses. Stability is pH-dependent and reduced under alkaline conditions or prolonged heat exposure. No caloric value, fat, carbohydrate, or protein content is applicable at therapeutic doses used in research (typically 1–20 mg/kg in preclinical models).

Preparation & Dosage

No clinically studied dosage ranges for salvianolic acid A are provided in the available research. The compound exists in various forms within Salvia miltiorrhiza extracts, but standardization protocols and therapeutic doses have not been established in the provided sources. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other salvianolic acids (B, C), caffeic acid, danshensu, rosmarinic acid

Safety & Interactions

Salvianolic acid A has not been studied in dedicated human safety trials, so a formal adverse effect profile has not been established. Because salvianolic acids from Dan Shen are known to inhibit CYP2C9 and P-glycoprotein activity, salvianolic acid A may potentiate the effects of anticoagulants such as warfarin, increasing bleeding risk. It should be used with caution alongside antiplatelet drugs (e.g., aspirin, clopidogrel) due to additive effects on platelet aggregation inhibition. Pregnant and breastfeeding women should avoid use given the absence of safety data in these populations.